AR and prostate carcinoma: As above-discussed, ~2% of prostate cancers at diagnosis exhibit a neuroendocrine phenotype; however, following treatment with AR pathway inhibitors, ~20–25% of patients relapse with tumors that have lost their AR dependence and have neuroendocrine features [678].